港股異動 | 再鼎醫藥-SB(9688.HK)4日反彈逾50% 日前獲股東增持2241萬港元
格隆匯3月21日丨日前創新低的再鼎醫藥-SB(9688.HK)4日累計反彈超50%,現漲11.21%,報311.44港元,總市值298億港元。公司於3月15日獲The Capital Group增持77.67萬股,涉資約2241.57萬港元。持股比例由4.25%上升至5.06%。興業證券此前表示,公司已上市產品在2022年有望實現銷售進一步放量增長,主要動力來自於醫保覆蓋擴大、新適應症獲批、以及公司商業化能力漸長;“授權+自研”的模式將持續擴充公司儲備產品管線,為未來收入持續增長奠定了堅實的基礎。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.